Sheets Smith Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Sheets Smith Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,915	Closed	-$1.01M	–	328
2017 Q3	$1.01M	Sell	11,915 -127	-1%	-$10.1K	0.26%	109
2017 Q2	$912K	Sell	12,042 -501	-4%	-$35K	0.24%	116
2017 Q1	$828K	Sell	12,543 -284	-2%	-$18.7K	0.22%	131
2016 Q4	$813K	Sell	12,827 -827	-6%	-$52.2K	0.23%	121
2016 Q3	$869K	Sell	13,654 -571	-4%	-$41.9K	0.25%	120
2016 Q2	$1.06M	Buy	+14,225	New	+$1.06M	0.31%	92
2014 Q3	–	Sell	-15,043	Closed	-$585K	–	268
2014 Q2	$585K	Buy	15,043 +382	+3%	+$15.5K	0.16%	170
2014 Q1	$615K	Buy	+14,661	New	+$611K	0.17%	161

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sheets Smith Wealth Management's LGND Position: Q4 2017 in Review

Sheets Smith Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2017, closing a stake of 11,915 shares — an estimated $1.01M sold.

Sheets Smith Wealth Management first reported a position in LGND in Q1 2014 and held it in 8 quarters. The position peaked at $1.06M in Q2 2016. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

Sheets Smith Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Sheets Smith Wealth Management sold 11,915 Ligand Pharmaceuticals shares in Q4 2017, an estimated $1.01M.
Sheets Smith Wealth Management first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Sheets Smith Wealth Management's Ligand Pharmaceuticals position peaked at $1.06M in Q2 2016.
298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Sheets Smith Wealth Management's 13F filing for Q4 2017, filed 12 Jan 2018.